Chemotherapy and immunotherapy combinations for the treatment of leukemia

Share This Post

According to the results of the second phase of the study, the combination of standard-care chemotherapy drug azacitidine and the immune checkpoint inhibitor nivolumab nivolumab ) showed that the response rate and recurrence of patients with relapsed or refractory acute myeloid leukemia ( AML ) The overall survival rate is encouraging.

The study followed 70 patients. After an average of 2 lines of treatment, relapsed AML reported an overall response rate of 33 % and a complete response rate of 22 %. The drug combination is particularly effective for patients who have not previously received hypomethylation agents ( HMA ) such as azacitidine or decitabine, and the total effective rate of these patients is 52 %.

The researchers said that bone marrow samples collected before treatment showed that the frequency of prediction of bone marrow CD3 and CD8 cells before treatment was higher. In particular, CD3 seems to have a high sensitivity and specificity rate to predict the response, indicating that it can be used as a reliable biomarker for selecting patients for this combination therapy. “

Treatment includes intravenous or subcutaneous injection of azacitidine and intravenous injection of nivolumab . Although most patients have been successfully treated, 11 % of patients still have serious or potentially life-threatening side effects. The overall survival of all patients was 6.3 months. The survival rate of patients with first relapse was 10.6 months, which was twice the survival rate observed with azacitidine alone in similar patients in MD Anderson .

Researcher Daver said that the relevant randomized phase III study is ongoing, and we believe that the implementation of clinical and immune biomarkers for selecting patients may result in further improvements in these types of therapies in AML .

https://medicalxpress.com/news/2018-11-combination-chemotherapy-immunotherapy-effective-phase.html

Website |  + posts

Susan Hau is a distinguished researcher in the field of cancer cell therapy, with a particular focus on T cell-based approaches and cancer vaccines. Her work spans several innovative treatment modalities, including CAR T-cell therapy, TIL (Tumor-Infiltrating Lymphocyte) therapy, and NK (Natural Killer) cell therapy.

Hau's expertise lies in cancer cell biology, where she has made significant contributions to understanding the complex interactions between immune cells and tumors.

Her research aims to enhance the efficacy of immunotherapies by manipulating the tumor microenvironment and exploring novel ways to activate and direct immune responses against cancer cells.

Throughout her career, Hau has collaborated with leading professors and researchers in the field of cancer treatment, both in the United States and China.

These international experiences have broadened her perspective and contributed to her innovative approach to cancer therapy development.

Hau's work is particularly focused on addressing the challenges of treating advanced and metastatic cancers. She has been involved in clinical trials evaluating the safety and efficacy of various immunotherapy approaches, including the promising Gamma Delta T cell therapy.

Subscribe To Our Newsletter

Get updates and never miss a blog from Cancerfax

More To Explore

Advancements in adoptive CAR immune cell immunotherapy synergistically combined with multimodal approaches for tumor treatment
CAR T-Cell therapy

Advancements in adoptive CAR immune cell immunotherapy synergistically combined with multimodal approaches for tumor treatment

CAR T cell therapy has transformed cancer treatment, especially in hematological malignancies. Treatment of solid tumors remains challenging due to their immunosuppressive tumor microenvironment. Combination with chemotherapy, immune checkpoint inhibitors, oncolytic viruses, and improved genetic engineering holds promise. Multimodal approaches enhance immune cell infiltration and persistence, raising efficacy. Evolving personalized methods will be instrumental in overcoming solid tumor resistance and improving patient outcomes.

How to prevent infections in patients receiving CD19-targeted chimeric antigen receptor T cells for B-cell malignancies
CAR T-Cell therapy

How to prevent infections in patients receiving CD19-targeted chimeric antigen receptor T cells for B-cell malignancies?

CAR T-cell therapy revolutionized cancer therapy, offering incredible success in the management of B-cell malignancies, but it is associated with severe infection risks secondary to immunosuppression. Preventive measures are pre-infusion screening, vaccination, and antimicrobial prophylaxis. Post-infusion, close surveillance for infection and cytokine release syndrome management are key. Long-term care includes the treatment of hypogammaglobulinemia, revaccination, and patient education. The approach ensures improved outcomes and reduces infection-related complications in patients receiving CD19-targeted CAR T-cell therapy.

Need help? Our team is ready to assist you.

We wish a speedy recovery of your dear and near one.

Start chat
We Are Online! Chat With Us!
Scan the code
Hello,

CancerFax is the most trusted online platform dedicated to connecting individuals facing advanced-stage cancer with groundbreaking cell therapies.

Send your medical reports and get a free analysis.

🌟 Join us in the fight against cancer! 🌟

Привет,

CancerFax — это самая надежная онлайн-платформа, призванная предоставить людям, столкнувшимся с раком на поздних стадиях, доступ к революционным клеточным методам лечения.

Отправьте свои медицинские заключения и получите бесплатный анализ.

🌟 Присоединяйтесь к нам в борьбе с раком! 🌟